• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    R

    Roskilde Sygehus

    EST. 1855
    1,067论文总数
    2.3万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1067)

    年份
    起
    –
    止
    排序
    1Hydralazine-isosorbide Dinitrate in Chronic Heart Failure with Reduced Ejection Fraction: the H-HeFT Trial
    Lars Køber, Kim Wadt Skak-Hansen,Anders Hostrup Larsen,Søren Vraa,Morten Schou,Dan Eik Høfsten, Jens Refsgaard, Flemming Steffensen,Christian Hassager,Erik Parner,Jacob Møller,Hans Eiskjær,

    Abstract Background and Aims Hydralazine-isosorbide dinitrate (H-ISDN) has shown benefit in earlier randomized trials of patients with reduced left ventricular ejection fraction (LVEF) and chronic heart failure. This trial tested if H-ISDN could reduce worsening heart failure or mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF) receiving contemporary treatment. Methods The Hydralazine-Isosorbide Dinitrate in Patients With Chronic Heart Failure Trial (H-HeFT) was a multicentre, randomized (1:1), double-blind, placebo-controlled trial in patients with HFrEF at 23 Danish hospitals (New York Heart Association class II–IV, elevated N-terminal pro-B-type natriuretic peptide and LVEF ≤40%). Target treatment was hydralazine 75 mg/isosorbide dinitrate 40 mg three times a day (t.i.d). The primary endpoint was a composite of hospitalization with worsening heart failure, an urgent outpatient visit resulting in intravenous/metolazone therapy for heart failure, heart transplantation, left ventricular assist device implantation, or death. Secondary endpoints included components of the primary outcome. Results Overall, 592 predominantly White patients (median age 72 years, 18% women) were randomized with a mean follow-up of 3.7 years. The primary outcome occurred in 90 of 294 patients (30.6%) in the H-ISDN group and in 91 of 298 patients (30.5%) in the placebo group [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.67–1.21; P = .48]. There were 57 deaths in the H-ISDN group vs 72 in the placebo group (HR 0.72; 95% CI 0.51–1.02); worsening heart failure events occurred in 52 vs 47 patients (HR 1.01; 95% CI 0.68–1.50). Conclusions Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF ≤40%.

    2026European Heart Journal(2026)
    引用
    AI阅读
    加入学术空间
    2Association Between 3D Left Atrial Strain and Device-Detected Atrial Fibrillation in a High-Risk General Population: Results from the LOOP Study
    M Yafasov, S Z Diederichsen, P G Joergensen, M T Jensen, A Dahl, N E Landler, C Graff, Brandes A, K Haugan, L Koeber, H Soeren, J H Svendsen,

    Abstract Background Measures of left atrial (LA) function are strongly associated with atrial fibrillation (AF). Three-dimensional echocardiography (3D) enables more precise geometric assessment than conventional 2D echocardiography and may offer incremental value to standard measures. Purpose To investigate the association between 3D LA strain and AF in a high-risk population. Methods We used data from the randomized controlled LOOP study which included elderly (≥70 years) with at least one stroke risk factor (hypertension, diabetes, heart failure, or prior stroke), who were randomized to implantable loop recorder (ILR) monitoring or usual care. Participants who had an ILR implanted and underwent 3D echocardiography were included. 3D-reservoir strain (3D-LASr), conduit strain (3D-LAScd), and contraction strain (3D-LASct) was quantified. The endpoints were incident device-detected AF ≥6 minutes and ≥24 hours. Associations between strain and AF were evaluated using Cox regression. Multivariable analysis was adjusted for the CHARGE-AF risk score (age, height, weight, blood pressure, smoking, hypertension, diabetes, congestive heart failure, history of myocardial infarction). Incremental prognostic value was assessed using C-statistics. Results The study included 819 participants, all underwent 3D echocardiography and had an ILR implanted. Mean age was 74.2±3.9 years, 638 (53%) were male. During a median follow-up time of 4.3 years (IQR 2.2-5.5 years), 236 (28.8%) participants had device-detected AF ≥6 minutes, and 34 (4.2%) AF ≥24 hours. Mean 3D-LA 3D-LASr was 20.7%, 3D-LAScd was 8.9%, and 3D-LASct was 11.9%. In univariable analysis 3D-LASr (HR 1.03 (95% CI 1.01-1.05); p=0.015, per 1 % decrease) and 3D-LASct (HR 1.05 (95% CI 1.02-1.07); p<0.001), per 1 % decrease), but not 3D-LAScd (HR 0.98 (95% CI 0.96-1.01); p=0.15, per 1% decrease) were associated AF≥6 minutes (Figure 1). These findings persisted after multivariable adjustment: 3D-LASr (HR 1.03 (95% CI 1.00-1.05); p=0.017, per 1% decrease) and 3D-LASct (HR 1.05 (95% CI 1.02-1.07); p<0.001, per 1% decrease). Similar findings were observed for ≥24-hour device detected AF in unadjusted analysis (Figure 2), and after multivariable adjustment (3D-LASr: HR 1.12 (95% CI 1.05-1.18); p=0.001, per 1% decrease; 3D-LASct: HR 1.16 (95% CI 1.08-1.24); p<0.001, per 1% decrease). When the continuous 3D variables were added to the CHARGE-AF score, 3D-LASct increased the C-statistic for both AF≥6 minutes (change in C-statistic 0.528 to 0.584, p =0.011) and AF≥24 hours (0.61 to 0.71, p =0.042) whereas 3D-LASr did not. Given association between 3D-LASr and outcomes were non-linear (p for nonlinearity<0.05), further studies are needed to evaluate whether 3D-LASr adds incremental value. Conclusion In a high-risk population, 3D reservoir and contraction strain were independently associated with device-detected AF, and 3D contraction strain adds incremental value to clinical risk scores.

    2026European Heart Journal(2026)
    引用
    AI阅读
    加入学术空间
    3Active Surveillance of JAK2V617F Clonal Hematopoiesis Toward Myeloproliferative Neoplasms
    Lea Löffler, Isabella Diana Davidsen,Vibe Skov,Lasse Kjær, Sabrina Cordua Bech,Christina Schjellerup Eickhardt‐Dalbøge,Sarah Friis Christensen,Trine Alma Knudsen, Anders Lindholm Soerensen,Morten Dahl,Claus Henrik Nielsen,Troels Wienecke,

    The aim was to characterize longitudinal JAK2V617F (JAK2) variant allele frequency (VAF) trajectories in individuals without MPN undergoing active surveillance, and to assess whether MPN can be detected at an earlier stage, resulting in lower clonal burden and less bone marrow fibrosis. In the Danish General Suburban Population Study (N=19,958, 2010-2013), we used retrospective measurement of JAK2 on biobanked samples in 2016-2017 and identified 92 JAK2-positive individuals with VAF≥1% that were without MPN at baseline in 2010-2013. Of these, 20 were diagnosed with MPN by clinical referral between 2010-2018. The remaining 72 were reinvited for active MPN surveillance (2018-2026), of whom 61 are included in the present study. Longitudinal JAK2 VAF was quantified using droplet digital PCR, and mixed-effects models were used to estimate clonal growth and blood cell trajectories. Median follow-up to MPN diagnosis was 7.4 years. Referral-diagnosed MPN cases exhibited a relative clonal growth rate of 34.3% per year (p<0.001). Among the 61 undergoing surveillance, 20 were diagnosed with MPN, exhibiting a relative clonal growth rate of 12.7% per year (p=0.003), whereas the remaining 41 did not develop MPN nor showed VAF progression (p=0.628). Within-individual and between-individual variance in VAF was 4.9% and 95.1%, respectively. Platelet counts increased 10.3×10⁹/L/year for surveillance-detected MPN and 44.5×10⁹/L/year for referral-diagnosed MPN. Surveillance-detected MPN had lower VAF at diagnosis (median 13.0% vs 41.3%) and less bone marrow fibrosis (grade 0: 80% vs 15%) than referral-diagnosed MPN. Active surveillance detects MPN with lower clonal burden and less bone marrow fibrosis.

    2026Blood Advances(2026)
    引用
    AI阅读
    加入学术空间
    4Open or Endovascular Repair: That is the Popliteal Question
    Egle Kavaliunaite,Martin Björck
    2026European journal of vascular and endovascular surgery the official journal of the European Society ...(2026)
    引用
    AI阅读
    加入学术空间
    5Vaccine Effectiveness of RSV Prefusion F Protein-Based Vaccination in Older Adults with Neurological or Cerebrovascular Disease: the DAN-RSV Trial
    Marat Yafasov, Mats H Lassen,Niklas Dyrby Johansen,Sine Hoejlund Christensen,Negar Aliabadi,Kristoffer G Skaarup,Daniel Modin,Brian Claggett,Carsten S Larsen,Lykke Larsen,Lothar Wiese,Michael Dalager-Pedersen,

    Objective: To evaluate the vaccine effectiveness (VE) of RSVpreF compared with no vaccination among adults with and without neurological or cerebrovascular disease. Background: Adults with neurological or cerebrovascular disease have an elevated risk of severe outcomes following respiratory syncytial virus infection. Whether vaccination with an RSV prefusion F protein-based vaccine reduces respiratory and cardiovascular outcomes in this population is uncertain. Design/methods: We conducted a prespecified secondary analysis of the DAN-RSV trial, a pragmatic, open-label, individually randomized controlled trial in Denmark. Adults aged 60 years or older were randomized 1:1 to RSVpreF vaccination or no vaccine. Outcomes were obtained from nationwide health registries. The primary outcome was hospitalization for RSV-related respiratory tract disease (RTD). VE was estimated as one minus the incidence rate ratio, expressed as percentage. Results: In total, 65,642 were randomized to RSVpreF and 65,634 to no vaccine. The incidence rate of almost all outcomes was higher among the 7,223 participants with neurological/cerebrovascular disease as compared to the 124,059 without. VE for RSV-related RTD hospitalization was 100% (0 vs 1 event; 95% CI; not calculable; number needed to vaccinate (NNV)=1506) among participants with neurological/cerebrovascular disease and 82.4% (95% CI, 39.0–96.7; NNV=1844) among those without. Comparing those with neurological/cerebrovascular disease to those without, VE for all-cause RTD hospitalization was 28.1% (95% CI -18.0-58.8; NNV 141) vs 13.5% (95% CI -2.6-27.0%; NNV 643), VE for all-cause cardiorespiratory hospitalization was 17.4% (95% CI -10.6-41.1; NNV=92) vs 8.9% (95% CI -1.7-18.2; NNV=412), VE for stroke 43.1 (95% CI -33.7-78.3; NNV=218) vs 15.0% (95% CI -17.4-38.4%; NNV=1981). The effect of vaccination was consistent regardless of neurological/cerebrovascular disease status (P interaction for all>0.05). Neurological outcomes were neutral for neurological hospitalizations [VE 14.5% (95% CI, -10.0 to 33.9); NNV=1345] and all-cause dementia favored RSVpreF [VE 20.7% (95% CI, -12.2 to 44.4)]. For Alzheimer’s dementia, treatment effect differed by baseline disease status (p=0.04), with reduced new-onset Alzheimer’s dementia among participants without baseline disease [VE 57.9% (95% CI, -0.8 to 84.1); P=0.041]. Conclusions: RSVpreF vaccination showed similar VE across subgroups. For all-cause outcomes, estimated NNV trended lower for those with underlying neurological or cerebrovascular disease due to a combination of higher VE point estimates and higher underlying rates of disease. RSVpreF vaccination was not associated with an increased risk of neurological hospitalizations, supporting neurological safety, while dementia outcomes showed a trend towards favoring RSVpreF vaccination.

    2026Circulation(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1067 篇论文

    合作机构(100)

    哥本哈根大学合作论文 168
    奥胡斯大学医院合作论文 115
    Odense University Hospital合作论文 112
    哥本哈根大学医院合作论文 90
    奥尔堡大学医院合作论文 71
    Herlev Hospital合作论文 71
    Bispebjerg Hospital合作论文 57
    奥胡斯大学合作论文 56
    南丹麦大学合作论文 42
    Rigshospitalet合作论文 41

    机构统计